The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
Cost -effectiveness analysis on medication schemes for acute cerebral infarction under clinical pathway
Author(s): 
Pages: 609-611
Year: Issue:  10
Journal: Qilu Pharmaceutical Affairs

Keyword:  Clinical pathwayAcute cerebral infarctionPharmacoeconomicsCost - effectiveness analysis;
Abstract: Objective To analysis the cost - effectiveness on medication schemes for acute cerebral infarction under clinical pathway. Methods A total of 630 patients with acute cerebral infarction in four hospital from Jan 2012 to Jun 2013 were assigned into three groups,Z( Chinese patent medicine)group,210 cases;H( chemical)group,210 cases;L (drug combination)group,210 cases. The course of treatment was 14 days. A cost - effectiveness ananlysis of pharmacoeco-nomics was then conducted. Results The average cost of 3 groups was 3 235. 8 yuan,3 695. 04 yuan and 4 605. 8 yuan,the effective rate of 3 groups was 65. 24% ,77. 14% ,92. 86%. Conclusion Among the 3 schemes group L1 was the best one.
Related Articles
No related articles found